Xenon Pharmaceuticals Current Ratio Growth & History (XENE)
Xenon Pharmaceuticals's current ratio was 13.42 for fiscal 2025.
View full Xenon Pharmaceuticals company overviewXenon Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 13.42 | −4.43 | −24.84% |
| 2024 | 2024-12-31 | 17.85 | −5.80 | −24.52% |
| 2023 | 2023-12-31 | 23.65 | −2.79 | −10.57% |
| 2022 | 2022-12-31 | 26.44 | −12.59 | −32.25% |
| 2021 | 2021-12-31 | 39.03 | 26.73 | +217.38% |
| 2020 | 2020-12-31 | 12.30 | 8.96 | +268.27% |
| 2019 | 2019-12-31 | 3.34 | −26.12 | −88.66% |
| 2018 | 2018-12-31 | 29.46 | 18.48 | +168.34% |
| 2017 | 2017-12-31 | 10.98 | −7.34 | −40.06% |
| 2016 | 2016-12-31 | 18.31 | −3.56 | −16.29% |
| 2015 | 2015-12-31 | 21.88 | 15.93 | +267.96% |
| 2014 | 2014-12-31 | 5.95 | 3.21 | +117.03% |
| 2013 | 2013-12-31 | 2.74 | — | — |
Xenon Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.02 | 5.88 | +38.83% |
| Q1 2026 | 2026-03-31 | 27.79 | 10.14 | +57.42% |
| Q4 2025 | 2025-12-31 | 13.42 | −4.43 | −24.84% |
| Q3 2025 | 2025-09-30 | 12.52 | −9.69 | −43.62% |
| Q2 2025 | 2025-06-30 | 15.14 | −8.14 | −34.96% |
| Q1 2025 | 2025-03-31 | 17.66 | −14.17 | −44.52% |
| Q4 2024 | 2024-12-31 | 17.85 | −5.80 | −24.52% |
| Q3 2024 | 2024-09-30 | 22.21 | 0.75 | +3.51% |
| Q2 2024 | 2024-06-30 | 23.27 | 3.93 | +20.33% |
| Q1 2024 | 2024-03-31 | 31.82 | 8.11 | +34.20% |
| Q4 2023 | 2023-12-31 | 23.65 | −2.79 | −10.57% |
| Q3 2023 | 2023-09-30 | 21.46 | −20.32 | −48.64% |
| Q2 2023 | 2023-06-30 | 19.34 | −38.52 | −66.57% |
| Q1 2023 | 2023-03-31 | 23.71 | −44.64 | −65.31% |
| Q4 2022 | 2022-12-31 | 26.44 | −12.59 | −32.25% |
| Q3 2022 | 2022-09-30 | 41.78 | 21.85 | +109.57% |
| Q2 2022 | 2022-06-30 | 57.86 | 40.06 | +224.98% |
| Q1 2022 | 2022-03-31 | 68.36 | 43.71 | +177.32% |
| Q4 2021 | 2021-12-31 | 39.03 | 26.73 | +217.38% |
| Q3 2021 | 2021-09-30 | 19.94 | 8.42 | +73.13% |
| Q2 2021 | 2021-06-30 | 17.81 | 7.97 | +81.10% |
| Q1 2021 | 2021-03-31 | 24.65 | 19.83 | +411.41% |
| Q4 2020 | 2020-12-31 | 12.30 | 8.96 | +268.27% |
| Q3 2020 | 2020-09-30 | 11.52 | 3.27 | +39.62% |
| Q2 2020 | 2020-06-30 | 9.83 | −1.24 | −11.22% |
| Q1 2020 | 2020-03-31 | 4.82 | −12.75 | −72.57% |
| Q4 2019 | 2019-12-31 | 3.34 | −26.12 | −88.66% |
| Q3 2019 | 2019-09-30 | 8.25 | −21.10 | −71.89% |
| Q2 2019 | 2019-06-30 | 11.07 | −9.72 | −46.75% |
| Q1 2019 | 2019-03-31 | 17.57 | 7.90 | +81.58% |
| Q4 2018 | 2018-12-31 | 29.46 | 18.48 | +168.34% |
| Q3 2018 | 2018-09-30 | 29.34 | — | — |
| Q2 2018 | 2018-06-30 | 20.80 | — | — |
| Q1 2018 | 2018-03-31 | 9.68 | — | — |
| Q4 2017 | 2017-12-31 | 10.98 | −7.34 | −40.06% |
| Q4 2016 | 2016-12-31 | 18.31 | −3.56 | −16.29% |
| Q3 2016 | 2016-09-30 | 17.95 | 5.55 | +44.83% |
| Q2 2016 | 2016-06-30 | 18.23 | 12.04 | +194.59% |
| Q1 2016 | 2016-03-31 | 20.29 | 15.63 | +335.84% |
| Q4 2015 | 2015-12-31 | 21.88 | 15.93 | +267.96% |
| Q3 2015 | 2015-09-30 | 12.39 | 9.44 | +319.51% |
| Q2 2015 | 2015-06-30 | 6.19 | — | — |
| Q1 2015 | 2015-03-31 | 4.66 | — | — |
| Q4 2014 | 2014-12-31 | 5.95 | 3.21 | +117.03% |
| Q3 2014 | 2014-09-30 | 2.95 | — | — |
| Q4 2013 | 2013-12-31 | 2.74 | — | — |
Xenon Pharmaceuticals current ratio trends
Over the last five fiscal years, Xenon Pharmaceuticals's current ratio increased from 12.30 to 13.42, a change of 1.12. The latest reported quarter, Q2 2026, shows 21.02.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenon Pharmaceuticals source filings ↗